C

CASI Pharmaceuticals
D

CASI

2.37000
USD
-0.04
(-1.66%)
Market Closed
Volume
43
EPS
-2
Div Yield
-
P/E
-1
Market Cap
36,717,417
Related Instruments
    C
    CRMD
    -0.690
    (-6.38%)
    10.130 USD
    C
    CYTK
    -0.820
    (-1.61%)
    50.260 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    K
    KALA
    -0.16000
    (-2.33%)
    6.71000 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    More
News

Title: CASI Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.